272 related articles for article (PubMed ID: 24625564)
1. Prevalence of stroke and the need for thromboprophylaxis in young patients with atrial fibrillation: a cohort study.
Lin AH; Oakley LS; Phan HL; Shutt BJ; Birgersdotter-Green U; Francisco GM
J Cardiovasc Med (Hagerstown); 2014 Mar; 15(3):189-93. PubMed ID: 24625564
[TBL] [Abstract][Full Text] [Related]
2. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
[TBL] [Abstract][Full Text] [Related]
3. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score.
Lip GY; Skjøth F; Rasmussen LH; Larsen TB
J Am Coll Cardiol; 2015 Apr; 65(14):1385-94. PubMed ID: 25770314
[TBL] [Abstract][Full Text] [Related]
4. Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey.
Marcucci M; Lip GY; Nieuwlaat R; Pisters R; Crijns HJ; Iorio A
Am J Med; 2014 Oct; 127(10):979-986.e2. PubMed ID: 24838192
[TBL] [Abstract][Full Text] [Related]
5. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
Olesen JB; Torp-Pedersen C; Hansen ML; Lip GY
Thromb Haemost; 2012 Jun; 107(6):1172-9. PubMed ID: 22473219
[TBL] [Abstract][Full Text] [Related]
6. CHA
Kim TH; Yang PS; Kim D; Yu HT; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B; Lip GYH
Stroke; 2017 Nov; 48(11):2984-2990. PubMed ID: 28939672
[TBL] [Abstract][Full Text] [Related]
7. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience.
Barnes GD; Gu X; Haymart B; Kline-Rogers E; Almany S; Kozlowski J; Besley D; Krol GD; Froehlich JB; Kaatz S
Thromb Res; 2014 Aug; 134(2):294-9. PubMed ID: 24929840
[TBL] [Abstract][Full Text] [Related]
8. The Population-Based Long-Term Impact of Anticoagulant and Antiplatelet Therapies in Low-Risk Patients With Atrial Fibrillation.
Golive A; May HT; Bair TL; Jacobs V; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
Am J Cardiol; 2017 Jul; 120(1):75-82. PubMed ID: 28483209
[TBL] [Abstract][Full Text] [Related]
9. [Comparison between CHADS2 score and CHA2DS2-VASc score on assessing the risk of ischemic stroke in patients with nonvalvular atrial fibrillation].
Xiang W; Wang Y; Liu F; Liu M; Feng X
Zhonghua Xin Xue Guan Bing Za Zhi; 2014 May; 42(5):389-91. PubMed ID: 25042916
[TBL] [Abstract][Full Text] [Related]
10. Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients.
Lip GY; Lanitis T; Mardekian J; Kongnakorn T; Phatak H; Dorian P
Stroke; 2015 Oct; 46(10):2830-7. PubMed ID: 26316345
[TBL] [Abstract][Full Text] [Related]
11. [Atrial fibrillation and stroke].
Aamodt AH; Sandset PM; Atar D; Tveit A; Russell D
Tidsskr Nor Laegeforen; 2013 Aug; 133(14):1453-7. PubMed ID: 23929293
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation.
Zhu WG; Xiong QM; Hong K
Tex Heart Inst J; 2015 Feb; 42(1):6-15. PubMed ID: 25873792
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial.
Apostolakis S; Lane DA; Buller H; Lip GY
Thromb Haemost; 2013 Nov; 110(5):1074-9. PubMed ID: 24048467
[TBL] [Abstract][Full Text] [Related]
14. Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable vascular disease: an era of new anticoagulants.
Turagam MK; Velagapudi P; Leal MA; Kocheril AG
Expert Rev Cardiovasc Ther; 2012 Apr; 10(4):433-9. PubMed ID: 22458577
[TBL] [Abstract][Full Text] [Related]
15. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?
Chao TF; Liu CJ; Wang KL; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chen TJ; Lip GY; Chen SA
J Am Coll Cardiol; 2015 Feb; 65(7):635-42. PubMed ID: 25677422
[TBL] [Abstract][Full Text] [Related]
16. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?
Roldán V; Marín F; Manzano-Fernandez S; Fernández H; Gallego P; Valdés M; Vicente V; Lip GY
Thromb Haemost; 2013 May; 109(5):956-60. PubMed ID: 23572113
[TBL] [Abstract][Full Text] [Related]
17. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients.
Wilke T; Groth A; Mueller S; Pfannkuche M; Verheyen F; Linder R; Maywald U; Kohlmann T; Feng YS; Breithardt G; Bauersachs R
Thromb Haemost; 2012 Jun; 107(6):1053-65. PubMed ID: 22398417
[TBL] [Abstract][Full Text] [Related]
18. Stroke prevention in elderly patients with atrial fibrillation.
Lew SJ; Lim JK
Singapore Med J; 2002 Apr; 43(4):198-201. PubMed ID: 12188065
[TBL] [Abstract][Full Text] [Related]
19. Which risk score best predicts perioperative outcomes in nonvalvular atrial fibrillation patients undergoing noncardiac surgery?
van Diepen S; Youngson E; Ezekowitz JA; McAlister FA
Am Heart J; 2014 Jul; 168(1):60-7.e5. PubMed ID: 24952861
[TBL] [Abstract][Full Text] [Related]
20. Pre-stroke CHADS2 and CHA2DS2-VASc scores are useful in stratifying three-month outcomes in patients with and without atrial fibrillation.
Tu HT; Campbell BC; Meretoja A; Churilov L; Lees KR; Donnan GA; Davis SM
Cerebrovasc Dis; 2013; 36(4):273-80. PubMed ID: 24135809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
